Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Springworks Therapeutics Inc (SWTX)

Springworks Therapeutics Inc (SWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,481,429
  • Shares Outstanding, K 75,323
  • Annual Sales, $ 191,590 K
  • Annual Income, $ -258,130 K
  • EBIT $ -184 M
  • EBITDA $ -275 M
  • 60-Month Beta 0.77
  • Price/Sales 18.13
  • Price/Cash Flow N/A
  • Price/Book 7.13

Options Overview Details

View History
  • Implied Volatility 45.28% ( -0.66%)
  • Historical Volatility 70.29%
  • IV Percentile 4%
  • IV Rank 21.05%
  • IV High 169.36% on 01/10/25
  • IV Low 12.20% on 04/28/25
  • Put/Call Vol Ratio 0.01
  • Today's Volume 2,428
  • Volume Avg (30-Day) 19,456
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 305,476
  • Open Int (30-Day) 226,624

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.73
  • Number of Estimates 4
  • High Estimate -0.49
  • Low Estimate -0.95
  • Prior Year -0.54
  • Growth Rate Est. (year over year) -35.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.08 +28.10%
on 04/16/25
46.31 -0.18%
on 05/01/25
+8.76 (+23.38%)
since 04/14/25
3-Month
32.83 +40.79%
on 04/09/25
62.00 -25.45%
on 02/20/25
-11.21 (-19.52%)
since 02/14/25
52-Week
28.21 +63.84%
on 10/24/24
62.00 -25.45%
on 02/20/25
+3.27 (+7.61%)
since 05/14/24

Most Recent Stories

More News
SpringWorks Therapeutics: Q1 Earnings Snapshot

SpringWorks Therapeutics: Q1 Earnings Snapshot

SWTX : 46.22 (unch)
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

SWTX : 46.22 (unch)
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

SWTX : 46.22 (unch)
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.

TNYA : 0.3879 (-1.65%)
CSCI : 3.45 (-1.29%)
MLYS : 15.11 (-0.53%)
SWTX : 46.22 (unch)
MGX : 1.5000 (-6.25%)
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

VTI : 289.41 (+0.07%)
XBI : 76.37 (-1.52%)
IWM : 206.78 (-0.89%)
SWTX : 46.22 (unch)
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

SWTX : 46.22 (unch)
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect

Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.

VTI : 289.41 (+0.07%)
XBI : 76.37 (-1.52%)
IWM : 206.78 (-0.89%)
SWTX : 46.22 (unch)
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

SWTX : 46.22 (unch)
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

SWTX : 46.22 (unch)
Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets

Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.

VTI : 289.41 (+0.07%)
XBI : 76.37 (-1.52%)
IWM : 206.78 (-0.89%)
SWTX : 46.22 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics...

See More

Key Turning Points

3rd Resistance Point 46.40
2nd Resistance Point 46.34
1st Resistance Point 46.28
Last Price 46.22
1st Support Level 46.16
2nd Support Level 46.10
3rd Support Level 46.04

See More

52-Week High 62.00
Fibonacci 61.8% 49.09
Last Price 46.22
Fibonacci 50% 45.10
Fibonacci 38.2% 41.12
52-Week Low 28.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar